MedTrace Logo

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules

NCT02667938 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 510

Last updated 2016-10-13

No results posted yet for this study

Summary

The main objective of this study is to evaluate efficacy and safety of HCP1301 capsule in patients with Benign Prostatic Hyperplasia and Erectile Dysfunction

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DRUG

HCP1303 capsule 5/0.2mg

DRUG

HCP1303 capsule 5/0.4mg

DRUG

HGP1201

DRUG

HCP1303 capsule 5/0.2mg placebo

DRUG

HCP1303 capsule 5/0.4mg placebo

DRUG

HGP1201 placebo

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Se Woong Kim, M.D.,Ph.D. · Catholic University of Seoul St.Mary's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-01-31
Completion
2016-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02667938 on ClinicalTrials.gov